Holen Sie sich die Stockscreener-App
27.30
3.96%
1.04
Handel nachbörslich:
27.34
0.04
+0.15%
Schlusskurs vom Vortag:
$26.26
Offen:
$26.6
24-Stunden-Volumen:
3.97M
Relative Volume:
1.52
Marktkapitalisierung:
$3.45B
Einnahmen:
$715.22M
Nettoeinkommen (Verlust:
$-250.10M
KGV:
-13.45
EPS:
-2.03
Netto-Cashflow:
$-205.58M
1W Leistung:
+5.57%
1M Leistung:
+14.80%
6M Leistung:
+42.11%
1J Leistung:
-17.27%
1-Tages-Spanne:
$26.19
$27.46
1-Wochen-Bereich:
$23.69
$27.46
52-Wochen-Spanne:
$16.10
$31.17
Apellis Pharmaceuticals Inc Stock (APLS) Company Profile
Firmenname
Apellis Pharmaceuticals Inc
Sektor
Branche
Telefon
617-977-5700
Adresse
100 FIFTH AVENUE, WALTHAM, KY
Vergleichen Sie APLS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
APLS
Apellis Pharmaceuticals Inc
|
27.30 | 3.32B | 715.22M | -250.10M | -205.58M | -2.03 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-06 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-10-15 | Eingeleitet | Wells Fargo | Overweight |
| 2025-09-26 | Herabstufung | Goldman | Neutral → Sell |
| 2025-05-09 | Herabstufung | BofA Securities | Buy → Neutral |
| 2025-05-09 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2025-04-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Herabstufung | Goldman | Buy → Neutral |
| 2024-11-21 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-10-25 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-16 | Eingeleitet | William Blair | Outperform |
| 2024-05-31 | Eingeleitet | Piper Sandler | Neutral |
| 2024-02-05 | Hochstufung | Jefferies | Hold → Buy |
| 2023-12-14 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-11-09 | Eingeleitet | Goldman | Buy |
| 2023-11-02 | Eingeleitet | Mizuho | Neutral |
| 2023-10-06 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2023-09-15 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-08-29 | Bestätigt | Citigroup | Buy |
| 2023-08-03 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2023-08-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-01-03 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-11-10 | Herabstufung | Jefferies | Buy → Hold |
| 2022-07-19 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-06-17 | Fortgesetzt | Stifel | Buy |
| 2022-04-14 | Herabstufung | ROTH Capital | Neutral → Sell |
| 2021-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2021-11-29 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2021-09-10 | Bestätigt | BMO Capital Markets | Outperform |
| 2021-09-10 | Bestätigt | Credit Suisse | Neutral |
| 2021-09-10 | Bestätigt | Needham | Buy |
| 2021-09-10 | Bestätigt | Oppenheimer | Outperform |
| 2021-09-10 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-08-19 | Eingeleitet | Jefferies | Buy |
| 2021-08-19 | Hochstufung | Wedbush | Neutral → Outperform |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-04-16 | Eingeleitet | Goldman | Buy |
| 2020-11-19 | Eingeleitet | Needham | Buy |
| 2020-09-01 | Eingeleitet | Stifel | Buy |
| 2020-07-20 | Eingeleitet | ROTH Capital | Buy |
| 2020-06-17 | Eingeleitet | BTIG Research | Neutral |
| 2020-04-01 | Eingeleitet | Raymond James | Strong Buy |
| 2020-03-31 | Eingeleitet | BMO Capital Markets | Outperform |
| 2020-03-11 | Hochstufung | Wedbush | Underperform → Neutral |
| 2020-01-07 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2019-12-19 | Eingeleitet | BofA/Merrill | Buy |
| 2019-11-22 | Eingeleitet | Wedbush | Underperform |
| 2019-11-05 | Eingeleitet | Credit Suisse | Neutral |
| 2019-08-01 | Bestätigt | Cantor Fitzgerald | Overweight |
| 2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-03-29 | Eingeleitet | Robert W. Baird | Outperform |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-07-30 | Hochstufung | B. Riley FBR | Neutral → Buy |
| 2018-05-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-04-12 | Herabstufung | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-02-08 | Eingeleitet | B. Riley FBR, Inc. | Buy |
Alle ansehen
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
Why (APLS) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Should You Be Concerned About Apellis Pharmaceuticals, Inc.'s (NASDAQ:APLS) ROE? - simplywall.st
Aug Breakouts: Is Apellis Pharmaceuticals Inc. stock near bottom after declineMarket Performance Recap & Daily Price Action Insights - ulpravda.ru
Can Apellis Pharmaceuticals Inc. stock sustain institutional interest2025 Investor Takeaways & AI Powered Buy/Sell Recommendations - ulpravda.ru
Can Apellis Pharmaceuticals Inc. (1JK) stock surprise with quarterly resultsJuly 2025 Weekly Recap & Risk Managed Investment Strategies - ulpravda.ru
Will Apellis Pharmaceuticals Inc. stock benefit from green energy trendsJuly 2025 Trends & Weekly Watchlist for Consistent Profits - ulpravda.ru
How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersBlue Chip Stock Analysis & Superior Wealth Strategies - bollywoodhelpline.com
How buybacks impact Apellis Pharmaceuticals Inc. stock value2025 Buyback Activity & Smart Swing Trading Techniques - ulpravda.ru
Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekers - ulpravda.ru
Apellis stock jumps nearly 8% as investors look to JPM healthcare update - TechStock²
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Navigating a 40.73% Potential Upside in the Biotech Space - DirectorsTalk Interviews
Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oklahoma City NewsThe Oklahoman - FinancialContent
Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN
Resistance Check: Is Apellis Pharmaceuticals Inc stock cheap at current valuation2025 Big Picture & Technical Pattern Based Buy Signals - moha.gov.vn
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Hold" from Analysts - MarketBeat
Simplify Asset Management Inc. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Institution Moves: How buybacks impact Apellis Pharmaceuticals Inc stock valueJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - moha.gov.vn
Apellis Pharmaceuticals' chief commercial officer sells shares worth $101,103 - MSN
Understanding Momentum Shifts in (APLS) - Stock Traders Daily
Highland Capital Management LLC Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - bollywoodhelpline.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX) - The Globe and Mail
Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating - 富途牛牛
Will Apellis Pharmaceuticals Inc. (1JK) stock outperform foreign stocksEarnings Risk Report & Reliable Volume Spike Trade Alerts - Улправда
Will Apellis Pharmaceuticals Inc. stock see PE expansion2025 Trading Recap & Reliable Price Breakout Signals - Улправда
Stifel maintains Apellis Pharmaceuticals (APLS) buy recommendation - MSN
APLS (Apellis Pharmaceuticals) EV-to-OCF : 39.23 (As of Dec. 19, 2025) - GuruFocus
Apellis Pharmaceuticals stock price target lowered to $48 at Stifel By Investing.com - Investing.com Canada
Stifel Lowers Price Target for Apellis Pharmaceuticals (APLS) to $48 | APLS Stock News - GuruFocus
Stifel Nicolaus Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00 - MarketBeat
Is Apellis Pharmaceuticals Inc. stock near bottom after decline2025 Pullback Review & AI Forecasted Entry and Exit Points - DonanımHaber
What technical charts say about Apellis Pharmaceuticals Inc. stock2025 Technical Overview & Comprehensive Market Scan Insights - Улправда
Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 5,000 Shares of Stock - MarketBeat
Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily
Officer Watson Sells 5,000 ($122.5K) Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan
Investors in Apellis Pharmaceuticals (NASDAQ:APLS) From Five Years Ago Are Still Down 54%, Even After 3.2% Gain This Past Week - 富途牛牛
Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets
Hudson Bay Capital Management LP Has $8.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis stock rating reiterated at Outperform by William Blair - Investing.com Canada
Squarepoint Ops LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Braidwell LP Sells 531,300 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
683 Capital Management LLC Buys 77,000 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha
Natixis Sells 564,361 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Camber Capital Management LP Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat
Apellis Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Low Cost Wealth Building - earlytimes.in
Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN
Apellis Pharmaceuticals, Inc. $APLS Shares Purchased by Amundi - MarketBeat
Finanzdaten der Apellis Pharmaceuticals Inc-Aktie (APLS)
Umsatz
Nettogewinn
Free Cashflow
ENV
Apellis Pharmaceuticals Inc-Aktie (APLS) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Baumal Caroline | Chief Medical Officer |
Jan 05 '26 |
Sale |
25.53 |
3,020 |
77,097 |
91,206 |
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):